Group 1: Company Strategy and Development - The company implements a "2+X" strategy focusing on innovative pharmaceuticals and agricultural chemicals CDMO business, establishing stable partnerships with leading global companies [2] - The production system is structured around "six cores + two collaborations," enhancing the R&D process from laboratory to commercial production [2][3] - The company aims to create a comprehensive "R&D-production" lifecycle chain to support high-end innovative products [2] Group 2: Agricultural Chemicals Business - The company has established a production capacity of 2,000 tons/year for chlorantraniliprole intermediates at the Nantong base, serving international agricultural clients for over a decade [3] - The Yancheng base has a production line for custom pesticide projects with an annual capacity of 500 tons, expected to start supplying next year [15] - The Lanzhou base has achieved a production capacity of approximately 500 tons/year for innovative pesticide intermediates, with an additional 1,000 tons/year capacity under installation [15] Group 3: Pharmaceutical Business - The company has over 20 years of experience in the pharmaceutical CDMO sector, providing comprehensive solutions from early drug development to commercial production [12] - The Taicang base has a production capacity of 60 tons/year for the raw material Levetiracetam, while the Malta base supports over 20 types of pharmaceutical raw materials [9] - The Lanzhou pilot base has established a production line for antiviral drug intermediates with an annual capacity of 15 tons [9] Group 4: Strategic Partnerships - The collaboration with Heng Rui Medicine exemplifies the company's "big client strategy," focusing on innovative product commercialization [12] - Plans for 2025 include launching 5-10 cooperative products, with at least 10 products planned for 2026 [11] - The partnership has expanded from small-scale experiments to comprehensive strategic cooperation across multiple therapeutic areas [12] Group 5: Future Outlook and Investment - The company is preparing to invest in new projects and expand production capacity, with over 100 acres of land reserved for future pharmaceutical and agricultural projects [9] - The company anticipates a gradual recovery in agricultural business performance as new projects are implemented [16] - Continuous investment in core technologies and service capabilities is expected to drive high-quality development in the pharmaceutical sector [12]